This genomic quiescence confirms that FAs do not require large-scale structural alterations for tumorigenesis and distinguishes them from phyllodes tumors, which typically acquire CNAs involving oncogenes (EGFR, PDGFB) or tumor suppressors (TP53, RB1). This evidence concerns the gene TP53 and phyllodes tumor.